Trust Signals
Key Takeaways
- Semaglutide is the only peptide in this list with large human RCTs: the STEP 1 trial (n=1961) showed roughly 15% body weight reduction over 68 weeks at 2.4 mg weekly.
- BPC-157 has compelling rodent healing data across dozens of published studies but lacks a completed Phase II or III human RCT as of mid-2026, placing it at Very Low confidence for human outcomes.
- CJC-1295 with DAC extends half-life from roughly 30 minutes to approximately 8 days via albumin binding, a pharmacokinetic feature that also raises pulsatility concerns not seen with shorter GHRH analogs.
- TB-500 is a synthetic fragment of Thymosin Beta-4 (roughly residues 17 to 23), not the full protein; most lab studies use the full protein, so direct TB-500 human data is essentially absent.
- A peptide COA without a named third-party HPLC lab and an endotoxin (LAL) result is a manufacturer self-report, not independent verification.
What Are the Top 5 Peptides Worth Knowing About?
The top 5 peptides most actively researched for body composition, recovery, and longevity are Semaglutide, BPC-157, CJC-1295 plus Ipamorelin, TB-500, and Sermorelin. Only Semaglutide and Sermorelin are FDA-approved. The others are research compounds with strong mechanistic rationale but limited human trial data. Evidence strength varies enormously across this list.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: How These 5 Compare on Human Data
- Semaglutide: The Only One With Phase III RCT Data
- BPC-157: Best Rodent Data, Missing Human Trials
- CJC-1295 Plus Ipamorelin: How the GH Axis Actually Works
- TB-500: What Most Pages Get Wrong About the Fragment
- Sermorelin: The Prescription Option With the Safest Profile
- Honest Head-to-Head: Peptides vs. Their Real Alternatives
- What Every Commodity Page Omits: Bioavailability, Purity, and Stability
- How to Read a Peptide Label and COA
- FAQ
- Sources
Evidence Ledger: How These 5 Compare on Human Data
| Peptide | Primary Use Claim | Best Evidence Type | Effect Direction | Confidence (Human Outcomes) |
|---|---|---|---|---|
| Semaglutide | Fat loss, glycemic control | Multiple large human RCTs (STEP, SUSTAIN series) | Strong positive for weight and HbA1c | High |
| Sermorelin | GH stimulation, body composition | Small human RCTs, FDA approval record | Positive for GH pulse amplitude; modest body composition signal | Moderate |
| CJC-1295 plus Ipamorelin | GH elevation, lean mass | Small human PK studies (CJC-1295 alone); combination largely animal/anecdotal | Positive GH elevation; body composition effects extrapolated | Low |
| BPC-157 | Tissue healing, gut repair | Rodent RCTs; one small human IBD pilot | Positive in animal models consistently | Very Low |
| TB-500 | Injury recovery, wound healing | Animal studies on full Thymosin Beta-4; TB-500 fragment data thinner still | Positive in animal wound and cardiac models | Very Low |
Semaglutide: The Only One With Phase III RCT Data
Semaglutide is a GLP-1 receptor agonist, a 31-amino-acid peptide with approximately 94% sequence homology to native human GLP-1, modified with a C18 fatty diacid chain at position 34 that enables albumin binding and substantially extends its circulating half-life. As described by Knudsen and Lau in their account of semaglutide's discovery and development (Frontiers in Endocrinology, 2019), this pharmacokinetic engineering is what enables once-weekly subcutaneous dosing; the albumin-binding modification slows renal clearance and protects the peptide from degradation by dipeptidyl peptidase-4. The resulting half-life is approximately one week, which is the basis for the weekly injection schedule used in clinical trials.
Mechanism with numbers: GLP-1 receptors in the hypothalamic arcuate nucleus and nucleus tractus solitarius mediate reduced appetite signaling. The STEP 1 trial (Wilding et al., NEJM 2021, n=1961) showed 14.9% mean body weight reduction at 68 weeks with 2.4 mg weekly semaglutide versus 2.4% with placebo. The STEP 4 trial demonstrated that discontinuation leads to substantial weight regain within a year, meaning the effect is maintenance-dependent, not curative.
What the mechanism does NOT prove: GLP-1 receptor activation also affects cardiac conduction, gastric motility, and pancreatic beta cells. The SELECT cardiovascular outcomes trial (Lincoff et al., NEJM 2023, n=17,604) showed a 20% reduction in major adverse cardiovascular events in overweight adults without diabetes, but this does not establish benefit in lean, metabolically healthy users, a population now driving off-label demand.
BPC-157: Best Rodent Data, Missing Human Trials
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of 15 amino acids derived from a sequence in human gastric juice protein. It is not endogenous in the same sense as BPC itself; the 157 designation refers to the specific fragment studied by Sikiric and colleagues at the University of Zagreb across a large body of rodent work published from the 1990s onward.
Mechanism with numbers: Rodent studies from Sikiric's group show upregulation of growth hormone receptor expression in tendon fibroblasts, activation of the FAK-paxillin pathway involved in cell migration, and modulation of nitric oxide synthesis. In rat Achilles tendon transection models, BPC-157-treated animals showed faster functional recovery and histologically denser collagen organization compared to controls. These are consistent, replicated animal findings. What they do not prove is equivalent healing acceleration in human tendons under clinical conditions.
The oral bioavailability exception: BPC-157 shows activity when administered orally or intraperitoneally in rodents, which is unusual for peptides. Researchers attribute this partly to resistance to pepsin digestion, though the exact mechanism of gut epithelial uptake is not fully characterized. This does not mean oral human bioavailability is clinically sufficient; it means BPC-157 is a better candidate for oral research than most peptides.
CJC-1295 Plus Ipamorelin: How the GH Axis Actually Works
This combination pairs two distinct receptor targets. CJC-1295 is a GHRH (growth hormone releasing hormone) analog that binds GHRH receptors on somatotroph cells in the anterior pituitary. Ipamorelin is a selective GHRP (growth hormone releasing peptide) that binds the ghrelin receptor (GHSR-1a), also on somatotrophs. Activating both pathways simultaneously produces a synergistic GH pulse greater than either alone, which is the pharmacological rationale for the combination.
CJC-1295 with vs. without DAC: The Drug Affinity Complex version covalently binds to plasma albumin via a lysine-maleimide reaction, extending half-life from roughly 30 minutes to approximately 8 days (Ionescu and Frohman, JCEM 2006, small human PK study). This produces a tonic elevation of GH baseline rather than discrete pulses. Normal GH physiology is highly pulsatile; the clinical significance of blunting this pulsatility with the DAC version is debated but is not a trivial concern.
Ipamorelin's selectivity advantage: Compared to older GHRPs like GHRP-6, Ipamorelin does not significantly elevate cortisol or prolactin at standard doses in animal studies. This selectivity is a real pharmacological advantage, though it has been characterized largely in preclinical models rather than large human trials.
TB-500: What Most Pages Get Wrong About the Fragment
The most consistent error on commodity peptide pages is treating TB-500 and Thymosin Beta-4 as interchangeable. They are not. Thymosin Beta-4 is a 43-amino-acid endogenous protein present in most mammalian cells that primarily sequesters G-actin, regulating cytoskeletal dynamics. TB-500 is a synthetic peptide corresponding to approximately residues 17 through 23 of Thymosin Beta-4, the fragment believed to confer most of the pro-healing and anti-inflammatory activity by promoting actin polymerization and upregulating integrin-linked kinase.
The translational problem: Most published research, including the cardiac repair studies (e.g., Bock-Marquette et al., Nature 2004) and wound healing work cited in review articles, used full-length Thymosin Beta-4, not the TB-500 fragment. Assuming the fragment produces identical effects to the full protein in humans requires an extrapolation that is not directly tested. The fragment may perform equivalently; it also may not. Human data for either form remains very limited.
WADA status: Thymosin Beta-4 (and by extension TB-500) is listed on the WADA Prohibited List under the category of peptide hormones and growth factors. Competitive athletes face sanctions regardless of the compound's regulatory status in their country.
Sermorelin: The Prescription Option With the Safest Profile
Sermorelin is a 29-amino-acid synthetic analog of endogenous GHRH (1-29 NH2), the minimal sequence required for full receptor binding and biological activity. It was FDA-approved for pediatric growth hormone deficiency and has a well-characterized safety record from that indication. Its use in adult longevity and body composition contexts is off-label but supported by a more substantial human pharmacology dataset than any non-approved peptide on this list.
Mechanism and feedback preservation: Because sermorelin acts at the hypothalamic-pituitary level and not by replacing GH directly, the normal somatostatin-mediated negative feedback loop remains intact. This means the pituitary retains sensitivity and self-regulation. Exogenous recombinant human GH (rhGH) bypasses this loop entirely and suppresses endogenous GH secretion with prolonged use. Sermorelin's half-life is roughly 10 to 20 minutes; it produces GH pulses rather than a flat pharmacological GH elevation.
Evidence quality note: Small RCTs in older adults (under 50 subjects) show increases in serum IGF-1 and modest improvements in body composition, but effect sizes are smaller than those seen with direct rhGH. This is the honest trade-off: a safer regulatory and physiological profile, but a less potent effect.
Honest Head-to-Head: Peptides vs. Their Real Alternatives
| Goal | Best Peptide Option | Real Alternative | Where Peptide Wins | Where Peptide Loses |
|---|---|---|---|---|
| Fat loss | Semaglutide | Tirzepatide (GIP + GLP-1) | Longer human safety record; more prescribers comfortable with it | SURMOUNT-1 trial showed tirzepatide achieved roughly 21% weight loss at highest dose vs. roughly 15% for semaglutide |
| GH elevation | Sermorelin or CJC-1295/Ipamorelin | Recombinant human GH (rhGH) | Preserves feedback loop; lower risk of supraphysiologic GH; no HPA axis suppression | Smaller magnitude GH elevation; weaker body composition effect size; more complex dosing |
| Tendon/ligament healing | BPC-157 | Platelet-rich plasma (PRP) injection | Oral or systemic dosing possible; lower cost per dose | PRP has small but existing human RCT data; BPC-157 has essentially none |
| Wound/tissue repair | TB-500 | Becaplermin (PDGF-BB gel, FDA-approved) | Potentially broader systemic application | Becaplermin has human RCT data for diabetic foot ulcers; TB-500 has none |
| Anti-aging GH support | Sermorelin | Tesamorelin (GHRH analog, FDA-approved for HIV lipodystrophy) | Lower cost; more widely compounded | Tesamorelin has better human efficacy data for visceral fat reduction in its studied population |
What Every Commodity Page Omits: Bioavailability, Purity, and Stability
The Oral Dosing Myth
The vast majority of peptides are cleaved by gastric acid (pH roughly 1.5 to 3.5) and brush-border peptidases before reaching systemic circulation. A peptide bond is an amide bond; amide hydrolysis is catalyzed by acid and by serine proteases (trypsin, chymotrypsin, pepsin). Most research peptides have no protective modification and no absorption enhancer, so oral bioavailability is negligible. BPC-157 is a partial exception due to its reported acid stability, but "detectable oral activity in rodents" is not the same as "clinically bioavailable in humans." Semaglutide oral form (Rybelsus) achieves roughly 1% bioavailability using the SNAC absorption enhancer under strict fasting conditions. Without that pharmaceutical engineering, the peptide would not survive the stomach.
Purity: What 98% Actually Means
HPLC purity of 98% means 98% of the UV-absorbing material at the measured wavelength is the target peptide. The remaining 2% can include truncated sequences, deletion sequences, and oxidized variants (methionine oxidation and cysteine oxidation are common synthetic byproducts). It does not tell you about endotoxin content. Bacterial endotoxins (lipopolysaccharides) are heat-stable, injection-grade hazardous contaminants that are undetected by HPLC. A product can be 99% pure by HPLC and cause a serious pyrogenic reaction if it was not synthesized under controlled endotoxin conditions. This is why an LAL (Limulus Amebocyte Lysate) endotoxin test is non-optional for any peptide intended for injection.
Stability After Reconstitution
Lyophilized peptides are kinetically stable because removing water suppresses hydrolysis and oxidation. Once reconstituted in bacteriostatic water (0.9% benzyl alcohol), the clock starts. Peptide degradation in solution occurs via hydrolysis of labile peptide bonds (asparagine deamidation is especially fast), oxidation of methionine or tryptophan residues, and aggregation. Temperature matters: refrigerated storage at 4 degrees C slows all three pathways substantially compared to room temperature. The common instruction to use reconstituted peptide within 4 to 6 weeks is a conservative practical guideline, not a precise kinetic constant; some peptides degrade faster, some slower, depending on sequence and formulation. Repeated freeze-thaw cycles are harmful because ice crystal formation mechanically disrupts peptide structure and the expansion-contraction cycle promotes aggregation.
How to Read a Peptide Label and COA
What Must Appear on the Vial Label
- Peptide name and sequence (or at minimum the established research name)
- Quantity in milligrams (not international units, which are concentration-dependent)
- Lot or batch number traceable to the COA
- Recommended storage conditions
- For compounded products: compounding pharmacy name, prescriber name, patient name, preparation date, and beyond-use date
Reconstitution Math
If you have a 5 mg vial and add 2.5 mL of bacteriostatic water, the concentration is 2 mg per mL (2000 mcg per mL). A 300 mcg dose equals 0.15 mL. Most insulin syringes read in units where 100 units equals 1 mL, so 0.15 mL equals 15 units on such a syringe. Confirming this math before each dose prevents significant under- or over-dosing.
COA Minimum Requirements
| Test | Method | Minimum Acceptable Result | Red Flag |
|---|---|---|---|
| Purity | HPLC (reverse-phase) | 98% or higher | Below 95%, or no method stated |
| Identity | Mass spectrometry (MS) | Molecular weight matches theoretical sequence weight | MS absent; only HPLC provided |
| Endotoxin | LAL assay | Less than 1 EU/mg for injectable use (USP guideline) | Not tested; or result absent |
| Appearance | Visual | White to off-white lyophilized powder | Yellow, brown, or visible particulate |
| Lab identity | Third-party lab name and date | Named independent laboratory | In-house only, or no lab named |
FAQ
What are the top 5 peptides with the strongest human evidence?
BPC-157, Semaglutide (GLP-1 class), CJC-1295/Ipamorelin, TB-500 (Thymosin Beta-4 fragment), and Sermorelin have the broadest research base. Semaglutide is the only one with multiple large human RCTs. The others range from small human trials to animal-only data.
Which peptide is best for body composition?
Semaglutide leads on fat loss in large RCTs (the STEP trials showed roughly 15% body weight reduction over 68 weeks in non-diabetic adults). GHRH/GHRP combinations like CJC-1295 plus Ipamorelin show modest lean mass benefits in smaller studies, but the effect size does not match GLP-1 agonist data.
Is BPC-157 backed by human trials?
Mostly no. The bulk of BPC-157 evidence is rodent studies showing accelerated tendon, ligament, and gut healing. One small human pilot for inflammatory bowel disease exists but is not definitive. The mechanism data is compelling, but human RCT evidence is currently very low quality.
What is the difference between CJC-1295 with and without DAC?
DAC (Drug Affinity Complex) extends the half-life of CJC-1295 from roughly 30 minutes to approximately 8 days by covalently binding the peptide to albumin in plasma. Without DAC, CJC-1295 acts more like a standard GHRH pulse. The long half-life version produces a prolonged GH baseline elevation rather than a pulse, which may blunt normal GH pulsatility.
Can peptides be taken orally?
Most research peptides cannot survive oral dosing intact. Gastric acid and brush-border peptidases cleave most sequences before systemic absorption. BPC-157 is a partial exception; rodent studies show oral activity, likely because it is partially acid-resistant. Semaglutide oral form (Rybelsus) uses an absorption enhancer (SNAC) and still requires a fasting protocol to reach meaningful bioavailability.
What is Thymosin Beta-4 and how does TB-500 differ from it?
Thymosin Beta-4 is a 43-amino-acid endogenous protein involved in actin sequestration and tissue repair. TB-500 is a synthetic peptide corresponding to the active fragment (roughly residues 17 to 23) believed to drive most of the healing activity. TB-500 is cheaper to synthesize and more practically dosed. Human evidence remains very limited.
How do I know if a research peptide is degraded?
Visible signs include cloudiness or particulate matter in a previously clear reconstituted solution, a yellow or brown tint in a solution that should be colorless, and a foul or unusual odor. Functionally, degraded peptide produces no effect at a dose that previously worked. A certificate of analysis (COA) from a third-party HPLC test is the only reliable pre-use check.
What does a peptide COA need to show to be trustworthy?
A credible COA must include HPLC purity (look for 98% or higher for research use), mass spectrometry confirmation of molecular weight matching the sequence, endotoxin testing (LAL assay), and the testing lab's name and date. Batch number on the vial should match the COA. A COA without a named third-party lab is essentially a manufacturer self-report.
Is Sermorelin safer than synthetic growth hormone?
Sermorelin stimulates endogenous GH release rather than replacing it, so it preserves the normal feedback loop. Exogenous rhGH bypasses the hypothalamic-pituitary axis entirely and can suppress endogenous production over time. Sermorelin also has a shorter half-life (roughly 10 to 20 minutes) and lower risk of supraphysiologic GH levels. However, head-to-head human RCT data comparing long-term safety profiles is limited.
Are these peptides legal to buy?
Legal status varies by country and compound. Semaglutide is FDA-approved as a drug and requires a prescription in the US. Sermorelin is also FDA-approved and prescription-only. BPC-157, TB-500, and CJC-1295/Ipamorelin are not FDA-approved for human use and are sold as research chemicals in the US. Compounded versions of some peptides exist via licensed compounding pharmacies. WADA bans several of these for competitive athletes.
How should research peptides be stored?
Lyophilized (freeze-dried) peptides are stable at room temperature for weeks to months when sealed, but long-term storage should be at 4 degrees C (refrigerator) or minus 20 degrees C (freezer). Once reconstituted in bacteriostatic water, most peptides should be refrigerated and used within 4 to 6 weeks. Repeated freeze-thaw cycles degrade the peptide chain via hydrolysis and aggregation.
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232.
- Knudsen LB, Lau J. The Discovery and Development of Semaglutide for the Treatment of Type 2 Diabetes. Frontiers in Endocrinology. 2019;10:155.
- Ionescu M, Frohman LA. Pulsatile Secretion of Growth Hormone (GH) Persists During Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797.
- Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. 2016;14(8):857-865.
- Bock-Marquette I, et al. Thymosin Beta-4 Activates Integrin-linked Kinase and Promotes Cardiac Cell Migration, Survival and Cardiac Repair. Nature. 2004;432(7016):466-472.
- Goldstein AL, et al. Thymosin Beta-4: A Multi-Functional Regenerative Peptide. Expert Opinion on Biological Therapy. 2012;12(Suppl 1):S37-S51.
- Walker RF. Sermorelin: A Better Approach to Management of Adult-Onset Growth Hormone Insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308.
- Jastrzebska-Stojko Z, et al. Pharmacology and Adverse Effects of Growth Hormone Secretagogues. Pharmaceuticals. 2021;14(8):793.
- World Anti-Doping Agency. Prohibited List 2024. WADA. Published January 2024.
- United States Pharmacopeia. General Chapter 85: Bacterial Endotoxins Test. USP-NF.
- Jorgensen JO, et al. Growth Hormone Administration by Subcutaneous Infusion Mimics Normal Physiological GH Secretion. European Journal of Endocrinology. 1990;123(1):67-72.
Footer Disclaimers
Platform: FormBlends is an informational and educational platform. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before using any compound described here.
Research Compound or Compounded Medication: BPC-157, TB-500, CJC-1295, and Ipamorelin are not FDA-approved for human therapeutic use. They are sold in the United States as research chemicals for laboratory use only. Sermorelin and Semaglutide are FDA-approved prescription medications; their use requires a valid prescription from a licensed prescriber.
Results: Individual results vary. Effect sizes described on this page reflect mean outcomes from specific clinical trials or animal studies under controlled conditions. They are not a guarantee or prediction of outcomes for any individual user.
Trademark: FormBlends and the FormBlends logo are trademarks of FormBlends. All other product names, compound names, and trial names referenced on this page are the property of their respective owners and are used here for identification and educational purposes only.